Magnesium in metabolic syndrome: a review based on randomized, double-blind clinical trials.
Study Goal
The researchers aimed to evaluate the efficacy of magnesium supplementation on components of metabolic syndrome (MetS), including insulin sensitivity, glucose, triglyceride, HDL-cholesterol levels, and blood pressure.
Results Summary
Magnesium supplementation was found to be effective in treating MetS, particularly in individuals with hypomagnesemia, improving key metabolic markers such as glucose, HDL-cholesterol, triglycerides, and blood pressure.
Population
Individuals with hypomagnesemia and metabolic syndrome.
Effective Dosage
Not specified
Duration
At least four weeks
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
magnesium | neutral | serum glucose | - | - | shows the effect | #1 |
magnesium | neutral | HDL-cholesterol | - | - | shows the effect | #2 |
magnesium | neutral | triglycerides levels | - | - | shows the effect | #3 |
magnesium | neutral | blood pressure | - | - | shows the effect | #4 |
magnesium supplementation | neutral | MetS | individuals with hypomagnesemia | - | can be effective in the treatment | #5 |
A growing body of evidence shows the effect of magnesium on serum glucose, HDL-cholesterol, and triglycerides levels, as well as on blood pressure, which strongly suggests that magnesium might play an important role in metabolic syndrome (MetS), a cluster of risk factors for cardiovascular disease and type 2 diabetes. We performed a systematic review of clinical evidence derived from randomized, double-blind, controlled clinical trials, regarding the efficacy of magnesium supplementation on the components of MetS. Using the electronic databases of Medline, Embase, and the Cochrane Controlled Trials Register up to May 2016, we looked for randomized controlled trials focused on the effects of oral magnesium supplementation on insulin sensitivity, glucose, triglyceride and HDL-cholesterol levels, as well as its effects on high blood pressure, irrespective of the magnesium salt used, and with a duration of at least four weeks. Crossover studies, irrespective of blinding criteria, were not included. Results of this review show that magnesium supplementation in individuals with hypomagnesemia can be effective in the treatment of MetS.